Contact
  • SARS-CoV-2

    ChLIA from EUROIMMUN

Anti-SARS-CoV-2 RBD ChLIA (IgG)

  • Chemiluminescence immunoassay for quantitative measurement of IgG against the receptor-binding domain (RBD) of SARS-CoV-2
  • Suited for the determination of the IgG antibody response following wild-type infections as well as vaccination with spike protein-based vaccines
  • Conversion into standardised units (BAU/ml) possible
  • Excellent agreement with the already established S1-based SARS-CoV-2 IgG ELISAs from EUROIMMUN
  • Exclusively processed automatically using the random access instruments IDS-i10 and IDS-iSYS Multi-Discipline Automated System (from software version 15.06a): continuous loading of patient samples for maximum flexibility

   

Product Ig class Format Included controls Order no. Status
Anti-SARS-CoV-2 RBD ChLIA (IgG) IgG 100 analyses,
4 x 5 ml
Additional product LI 2606-10010-1 G CE marked
Control set Anti-SARS-CoV-2 RBD ChLIA (IgG) IgG Pos. control,
neg. control
LR 2606-20210-1 G CE marked